As I understand it, the existing vaccine produces a robust increase in T-cells at the tumor. Is it known that adding what Ori can provide makes it even more robust? Gary
Maybe someone who knows the different capabilities of the 2023 version of Eden and the 2024 version that would not fit clean room parameters might like to chime in on this conversation. I believe the 2024 version was going to have desired expanded capabilities vs the 2013 model and that this 2024 model failure to launch might explain a little bit more about the possible connection to Ori. I’d like to stick with attempting to correctly address THIS issue and why it is or is not more likely related to the desired end products. By the way, I already discussed the heterogenous activation and differentiation types in DCs years ago and why understanding this has helped NWBO continue the path to improved proper activation and isolation of specific DC subtypes. One of those subtypes was at least initially identified as killer DCs; ). Best wishes.
Market Data 
Markets 
AI
